KPTI Karyopharm Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KPTI

Price (delayed)

$8.84

Market cap

$663.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.71

Enterprise value

$755.26M

Highlights
The company's gross profit has surged by 98% YoY and by 4.8% QoQ
The revenue has soared by 92% YoY and by 4.7% from the previous quarter
The equity has plunged by 178% from the previous quarter and by 124% YoY
Karyopharm Therapeutics's quick ratio has decreased by 46% YoY and by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://karyopharm.com/
Peers: MRK BMY ABT EXEL

Key stats

What are the main financial stats of KPTI
Market
Shares outstanding
75.09M
Market cap
$663.82M
Enterprise value
$755.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.67
Earnings
Revenue
$113.21M
EBIT
-$174.64M
EBITDA
-$173.67M
Free cash flow
-$168.25M
Per share
EPS
-$2.71
Free cash flow per share
-$2.26
Book value per share
-$0.53
Revenue per share
$1.52
TBVPS
$3.69
Balance sheet
Total assets
$274.91M
Total liabilities
$314.55M
Debt
$181.45M
Equity
-$39.64M
Working capital
$193.5M
Liquidity
Debt to equity
-4.58
Current ratio
4.12
Quick ratio
3.93
Net debt/EBITDA
-0.53
Margins
EBITDA margin
-153.4%
Gross margin
97.5%
Net margin
-177.3%
Operating margin
-156.2%
Efficiency
Return on assets
-61.5%
Return on equity
-357.7%
Return on invested capital
-54.5%
Return on capital employed
-82%
Return on sales
-154.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
-2.1%
1 week
-4.43%
1 month
-14.59%
1 year
-52.52%
YTD
-42.89%
QTD
-14.34%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$113.21M
Gross profit
$110.39M
Operating income
-$176.87M
Net income
-$200.76M
Gross margin
97.5%
Net margin
-177.3%
The company's gross profit has surged by 98% YoY and by 4.8% QoQ
The revenue has soared by 92% YoY and by 4.7% from the previous quarter
KPTI's operating margin is up by 46% YoY
KPTI's net margin is up by 44% YoY and by 2.4% from the previous quarter

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.67
The EPS has grown by 7% YoY
The equity has plunged by 178% from the previous quarter and by 124% YoY
The P/S is 99% lower than the 5-year quarterly average of 784.3 and 49% lower than the last 4 quarters average of 11.4
The revenue has soared by 92% YoY and by 4.7% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
The return on equity has dropped by 96% since the previous quarter and by 72% year-on-year
The ROS has grown by 46% YoY
Karyopharm Therapeutics's return on invested capital has increased by 19% YoY but it has decreased by 2.1% QoQ
KPTI's ROA is down by 13% QoQ and by 2.8% YoY

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 13% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has decreased by 46% YoY and by 11% from the previous quarter
The current ratio has contracted by 45% YoY and by 10% from the previous quarter
The equity has plunged by 178% from the previous quarter and by 124% YoY
KPTI's debt is up by 44% YoY and by 38% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.